Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the ...

Shernan Holtan, MD, has been named the recipient of 2025 Lukas D. Wartman Award. Holtan, chief of blood and marrow ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute ...

Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.

The following is a summary of “Rapid tapering of cyclosporine after allogeneic transplantation for high-risk hematological malignancies,” published in the February 2025 issue of International Journal ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...